bioAffinity Technologies, Inc. (BIAFW) stock
BIAFWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/3056% below fair value
$0.24+0.00 (0.00%)
Close on Oct 30, 2026Market cap $23.58MP/E –Yield –
bioAffinity Technologies operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
bioAffinity Technologies's operating cash flow for the twelve months ending Jun 30, 2026 was -$11.47M. For fiscal 2025 it was -$9.33M. The highest annual figure on record is -$2.05M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.33M | – |
| FY2024 | Dec 31, 2024 | -$7.26M | – |
| FY2023 | Dec 31, 2023 | -$6.04M | – |
| FY2022 | Dec 31, 2022 | -$4.07M | – |
| FY2021 | Dec 31, 2021 | -$2.05M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.20M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.64M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.71M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.53M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.62M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.53M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.36M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.53M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.30M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.76M | – |
| Q2 FY2022 | Jun 30, 2022 | -$376.14K | – |
| Q1 FY2022 | Mar 31, 2022 | -$633.97K | – |
| Q4 FY2021 | Dec 31, 2021 | -$652.44K | – |